Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Inclusion Criteria: * Neck and head epidermoid carcinoma histologically proved. Patient with an ENT epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet. * At least tumor classified T2NXM0 * Patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy) * Patient without clinical or radiological sign of metastatic disease * Good general status (OMS ≤ 2) * Patient able to ingest food. * Age ≥ 18 years * Well-informed written consent, signed by the patient. * Patient with sickness benefit Exclusion Criteria: * Patient with relapse ever treated by radiotherapy * Other prospective study's participation * Recent and massive digestive haemorrhage * Medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing. * Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome) * Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion. * Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier * Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization * Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion * Bilirubin at higher concentration than one point five times the normal * Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula * Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study * Pregnant or nursing women * Patient under guardianship or trusteeship.